| Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol SY Liu, R Aliyari, K Chikere, G Li, MD Marsden, JK Smith, O Pernet, ... Immunity 38 (1), 92-105, 2013 | 638 | 2013 |
| Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro BA DeChristopher, BA Loy, MD Marsden, AJ Schrier, JA Zack, PA Wender Nature chemistry 4 (9), 705-710, 2012 | 199 | 2012 |
| Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo EJ Beans, D Fournogerakis, C Gauntlett, LV Heumann, R Kramer, ... Proceedings of the National Academy of Sciences 110 (29), 11698-11703, 2013 | 169 | 2013 |
| HIV latency in the humanized BLT mouse MD Marsden, M Kovochich, N Suree, S Shimizu, R Mehta, R Cortado, ... Journal of virology 86 (1), 339-347, 2012 | 139 | 2012 |
| Activation of latent HIV using drug-loaded nanoparticles M Kovochich, MD Marsden, JA Zack PloS one 6 (4), e18270, 2011 | 116 | 2011 |
| Mosaic structure of the human immunodeficiency virus type 1 genome infecting lymphoid cells and the brain: evidence for frequent in vivo recombination events in the evolution … A Morris, M Marsden, K Halcrow, ES Hughes, RP Brettle, JE Bell, ... Journal of virology 73 (10), 8720-8731, 1999 | 109 | 1999 |
| In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell" kick" and" kill" in strategy for virus eradication MD Marsden, BA Loy, X Wu, CM Ramirez, AJ Schrier, D Murray, ... PLoS pathogens 13 (9), e1006575, 2017 | 96 | 2017 |
| Eradication of HIV: current challenges and new directions MD Marsden, JA Zack Journal of antimicrobial chemotherapy 63 (1), 7-10, 2009 | 84 | 2009 |
| Humanized mouse models for human immunodeficiency virus infection MD Marsden, JA Zack Annual review of virology 4, 393-412, 2017 | 83 | 2017 |
| Bioengineered vaults: Self-assembling protein shell–lipophilic core nanoparticles for drug delivery DC Buehler, MD Marsden, S Shen, DB Toso, X Wu, JA Loo, ZH Zhou, ... ACS nano 8 (8), 7723-7732, 2014 | 65 | 2014 |
| An immune control model for viral replication in the CNS during presymptomatic HIV infection M McCrossan, M Marsden, FW Carnie, S Minnis, B Hansoti, IC Anthony, ... Brain 129 (2), 503-516, 2006 | 65 | 2006 |
| HIV/aids eradication MD Marsden, JA Zack Bioorganic & medicinal chemistry letters 23 (14), 4003-4010, 2013 | 64 | 2013 |
| Generation of T lineage cells from human embryonic stem cells in a feeder free system Z Galić, SG Kitchen, A Subramanian, G Bristol, MD Marsden, ... Stem cells 27 (1), 100-107, 2009 | 55 | 2009 |
| Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents MD Marsden, X Wu, SM Navab, BA Loy, AJ Schrier, BA DeChristopher, ... Virology 520, 83-93, 2018 | 49 | 2018 |
| Studies of retroviral infection in humanized mice MD Marsden, JA Zack Virology 479, 297-309, 2015 | 48 | 2015 |
| Latency reversal plus natural killer cells diminish HIV reservoir in vivo JT Kim, TH Zhang, C Carmona, B Lee, CS Seet, M Kostelny, N Shah, ... Nature communications 13 (1), 121, 2022 | 46 | 2022 |
| Primary cell model for activation-inducible human immunodeficiency virus B Burke, HJ Brown, MD Marsden, G Bristol, DN Vatakis, JA Zack Journal of virology 81 (14), 7424-7434, 2007 | 46 | 2007 |
| Pharmacological activation of non-canonical NF-κB signaling activates latent HIV-1 reservoirs in vivo L Pache, MD Marsden, P Teriete, AJ Portillo, D Heimann, JT Kim, ... Cell Reports Medicine 1 (3), 2020 | 41 | 2020 |
| Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window JL Sloane, NL Benner, KN Keenan, X Zang, MSA Soliman, X Wu, ... Proceedings of the National Academy of Sciences 117 (20), 10688-10698, 2020 | 41 | 2020 |
| RNAi-mediated CCR5 knockdown provides HIV-1 resistance to memory T cells in humanized BLT mice S Shimizu, GE Ringpis, MD Marsden, RV Cortado, HM Wilhalme, ... Molecular Therapy-Nucleic Acids 4, 2015 | 41 | 2015 |
